NCI-MATCH (EAY131)
NCI-MATCH was the largest trial to sequence tumours from thousands of patients across the United States and give each a drug matched to the mutation rather than to the organ. It proved the system could work at national scale, found real activity for a handful of matches, and showed that most single drugs given for a single mutation do little.
Overview
NCI-MATCH opened in August 2015, run by ECOG-ACRIN for the National Cancer Institute with Keith Flaherty and Peter O'Dwyer as chairs and every NCI cooperative group taking part. Patients whose cancer had progressed on standard therapy, or who had a rare cancer with no standard, had a fresh biopsy sequenced in one of four accredited laboratories with a common assay, and a central rules engine matched alterations to treatment arms, each a single-arm phase 2 with objective response as the endpoint. The trial started with ten arms and grew to nearly 40, testing drugs including dabrafenib with trametinib, nivolumab, trastuzumab emtansine, capivasertib, copanlisib, palbociclib, sunitinib, binimetinib, afatinib, osimertinib, crizotinib, larotrectinib and adavosertib.
The screening results, in the Journal of Clinical Oncology in 2020, described 5,954 patients: sequencing succeeded in the great majority, more than a third had an alteration the trial deemed actionable, and 17.8 percent were assigned to an arm. Rare and less common cancers made up most of the enrolment, which made NCI-MATCH one of the biggest sources of rare-tumour genomics. Among the arms, dabrafenib plus trametinib in BRAF V600-mutant non-melanoma cancers (response rate 38 percent) and nivolumab in mismatch repair-deficient non-colorectal cancers (36 percent) were clearly positive and supported later tumour-agnostic thinking; capivasertib in AKT1-mutant tumours and copanlisib in PIK3CA-mutant tumours showed moderate activity; most arms matching a drug to an amplification, a loss-of-function change or a rarer kinase mutation did not reach their bar. A 2023 Nature Medicine paper drew the lessons together, and a 2024 Clinical Cancer Research analysis showed that activity often depended on tumour type as much as on the mutation.
What NCI-MATCH changed was infrastructure and expectations: a common national assay and rules engine, a precedent for enrolling rare cancers by mutation, and the recognition that genotype-only matching rarely suffices, which led directly to ComboMATCH (combinations chosen from preclinical evidence, opened 2023), myeloMATCH in leukaemia and the iMATCH immunotherapy programme. Its arms continue to be reported as follow-up matures.
- 17.8 out of 100 people reached this endpoint with Enrolled patients.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- 38 out of 100 people had their tumour shrink with Treated patients.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- 36 out of 100 people had their tumour shrink with Treated patients.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- These results apply to the people the trial enrolled: Advanced solid tumours, lymphomas and myeloma that have progressed on standard treatment: central tumour sequencing assigns patients to one of nearly 40 single-agent or doublet targeted-therapy arms by molecular alteration regardless of cancer type. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Similar pages
not linked directly; found by shared links- TrialALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
Shares Crizotinib, ECOG-ACRIN Cancer Research Group, Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials.
- TrialTAPUR (Targeted Agent and Profiling Utilization Registry)
Shares Cancer variant knowledgebases and molecular tumour boards, Crizotinib, Sunitinib, Master protocol (platform, basket and umbrella trials).
- TrialNational Lung Matrix Trial
Shares Crizotinib, Capivasertib, Master protocol (platform, basket and umbrella trials), Palbociclib.
- TrialI-PREDICT
Shares Cancer variant knowledgebases and molecular tumour boards, Master protocol (platform, basket and umbrella trials), Rare cancers, Basket, umbrella, and platform trials.
- TrialDART (SWOG S1609): nivolumab plus ipilimumab in rare tumours
Shares Master protocol (platform, basket and umbrella trials), Rare cancers, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets.
- TrialDETERMINE
Shares Master protocol (platform, basket and umbrella trials), Rare cancers, Tumour-agnostic (tissue-agnostic) approval, Basket, umbrella, and platform trials.
- TrialFOCUS4
Shares Adavosertib, Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials, Trial design, endpoints and cost.
- TrialLung-MAP (SWOG S1400 and S1900)
Shares ECOG-ACRIN Cancer Research Group, Master protocol (platform, basket and umbrella trials), Palbociclib, Basket, umbrella, and platform trials.